ArticleSleep & breathing = Schlaf & Atmung2026
Relationship between MSpO
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveThis study explored risk factors associated with depressive symptoms in older patients with obstructive sleep apnea (OSA) and assessed correlations of mean pulse oxygen saturation (MSpO
methodsIn total, 1,085 older patients diagnosed with OSA via polysomnography (PSG) were included. Based on scores from the 12-item Geriatric Depression Scale (GDS-12), participants were classified into two subgroups to identify depressive symptom-related risk factors. Logistic regression analysis, restricted cubic splines, and subgroup analyses were performed to evaluate correlations of MSpO
resultsDepressive symptoms were observed in 139 patients (12.8% of the sample). Logistic regression analysis indicated that age (per 1-year increase, odds ratio [OR] = 1.11, 95% confidence interval [CI]: 1.08-1.14; P < 0.001), smoking (OR = 1.66, 95% CI: 1.02-2.69; P = 0.041), MSpO₂ (per 1% increase, OR = 0.90, 95% CI: 0.85-0.94; P < 0.001), diabetes mellitus (OR = 1.61, 95% CI: 1.03-2.51; P = 0.038), and renal dysfunction (OR = 2.26, 95% CI: 1.10-4.66; P = 0.027) were significantly associated with depressive symptoms. Additionally, sleep parameters including AHI, ODI, and LSpO₂ were independently associated with depressive symptoms. Restricted cubic splines suggested a linear correlation between MSpO₂ and depressive symptoms (nonlinear P = 0.38). Compared with patients in the highest category (MSpO₂ ≥ 95.0%), those in the lowest category (MSpO₂ ≤ 91.7%) showed increased depressive symptom risk (OR = 2.25, 95% CI: 1.34-3.78, P = 0.002). Subgroup analyses confirmed this linear relationship.
conclusionA linear correlation exists between MSpO
Indexed as
Identifiers
42527741What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.